Financials NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-22 pm EST			5-day change	1st Jan Change
14.19 ^USD	+4.65%		+2.83%	+9.74%

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT

Projected Income Statement: NovoCure Limited

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	494.4	535	537.8	509.3	605.2	655.4	691	765.5
Change	-	8.23%	0.53%	-5.3%	18.82%	8.29%	5.43%	10.79%
EBITDA ¹	39.55	-34.08	-78.9	-221.9	-159.3	-145.6	-151.2	-100.4
Change	-	-186.17%	-131.5%	-181.25%	28.23%	8.6%	-3.85%	33.58%
EBIT ¹	30.4	-44.33	-89.52	-232.9	-170.5	-157.6	-156.9	-114.6
Change	-	-245.83%	-101.93%	-160.12%	26.78%	7.59%	0.43%	26.92%
Interest Paid ¹	-12.3	-7.742	7.677	-	-39.33	-13.4	-21	-14.5
Earnings before Tax (EBT) ¹	18.1	-52.08	-81.85	-191.7	-131.2	-135.3	-147.2	-111.8
Change	-	-387.68%	-57.17%	-134.27%	31.59%	-3.17%	-8.82%	24.06%
Net income ¹	19.81	-58.35	-92.53	-207	-168.6	-156.8	-171.3	-127.3
Change	-	-394.58%	-58.58%	-123.75%	18.55%	6.99%	-9.21%	25.71%
Announcement Date	2/25/21	2/24/22	2/23/23	2/22/24	2/27/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	144	134.7	133.5	133.6	133.2	137.5	140.9	131	128.4	122.2	126.1	127.3	133.8	138.5	150.4	155.1	161.3	155	158.8	167.2	174.4	168.3	170.6	174.4	177.4	172.3	175.7	181.6
Change	-	-6.43%	-0.87%	0.07%	-0.29%	3.25%	2.41%	-7.01%	-1.96%	-4.86%	3.17%	1.01%	5.08%	3.53%	8.56%	3.15%	3.98%	-3.89%	2.46%	5.29%	4.3%	-3.49%	1.34%	2.25%	1.7%	-2.88%	2%	3.33%
EBITDA ¹	14.56	2.282	-9.815	-5.818	-20.73	1.804	-18.47	-21.95	-40.28	-57.53	-59.94	-55.44	-48.99	-38.7	-30.72	-29.63	-60.2	-34.54	-36.08	-32.36	-42.58	-38.84	-35.85	-31.14	-32.6	-31.35	-36.63	-20.03
Change	-	-84.33%	-530.11%	40.72%	-256.33%	108.7%	-1,124.06%	-18.83%	-83.48%	-42.82%	-4.19%	7.5%	11.63%	21%	20.63%	3.54%	-103.15%	42.62%	-4.45%	10.31%	-31.59%	8.77%	7.72%	13.15%	-4.71%	3.85%	-16.84%	45.32%
EBIT ¹	12.09	-0.088	-12.3	-8.552	-23.4	-0.806	-21.13	-24.61	-42.98	-60.25	-62.66	-58.24	-51.72	-41.52	-33.58	-32.09	-63.3	-37.86	-39.52	-36.02	-44.15	-39.3	-39.62	-38.8	-40.24	-35.31	-30.64	-24.09
Change	-	-100.73%	-13,871.59%	30.44%	-173.6%	96.56%	-2,521.34%	-16.49%	-74.63%	-40.19%	-4%	7.05%	11.21%	19.72%	19.12%	4.43%	-97.26%	40.19%	-4.37%	8.86%	-22.58%	10.99%	-0.81%	2.07%	-3.71%	12.24%	13.23%	21.38%
Charge d'intérêts ¹	-3.267	-2.646	-0.94	-1.981	-2.175	-1.709	-2.228	1.194	10.42	-	-	-	-	-	-	-	-	-	-2.666	-2.837	-5.3	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	8.825	-2.734	-13.24	-10.53	-25.57	-2.515	-23.36	-23.42	-32.56	-51.08	-53.9	-48.22	-38.53	-31.64	-22.73	-21.58	-55.21	-30.3	-34.98	-30.02	-40.04	-34.54	-34.92	-33.97	-35.31	-29.31	-24.64	-18.09
Change	-	-130.98%	-384.09%	20.42%	-142.79%	90.17%	-828.67%	-0.26%	-39.04%	-56.89%	-5.53%	10.54%	20.09%	17.89%	28.17%	5.03%	-155.76%	45.12%	-15.46%	14.17%	-33.38%	13.75%	-1.11%	2.73%	-3.94%	16.97%	15.94%	26.58%
Net income ¹	4.917	-4.128	-14.64	-13.12	-26.46	-4.647	-24.01	-26.58	-37.3	-53.06	-57.42	-49.48	-47.08	-38.76	-33.38	-30.57	-65.92	-34.32	-40.14	-37.27	-45.13	-43.33	-43.58	-40.54	-40.14	-37.31	-32.64	-26.09
Change	-	-183.95%	-254.68%	10.36%	-101.6%	82.44%	-416.63%	-10.7%	-40.36%	-42.24%	-8.21%	13.82%	4.86%	17.67%	13.89%	8.4%	-115.64%	47.94%	-16.96%	7.15%	-21.09%	3.99%	-0.58%	6.96%	0.99%	7.05%	12.52%	20.07%
Announcement Date	2/25/21	4/29/21	7/29/21	10/28/21	2/24/22	4/28/22	7/28/22	10/27/22	2/23/23	5/4/23	7/27/23	10/26/23	2/22/24	5/2/24	7/25/24	10/30/24	2/27/25	4/24/25	7/24/25	10/30/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: NovoCure Limited

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	195	353	450	328	-164	-	-176	-
Change	-	81.03%	27.48%	-27.11%	-150%	-	-	-
Announcement Date	2/25/21	2/24/22	2/23/23	2/22/24	2/27/25	-	-	-

Estimates

Cash Flow Forecast: NovoCure Limited

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	14.97	24.17	21.36	27.09	42.86	17.9	30	31
Change	-	61.48%	-11.63%	26.85%	58.18%	-58.23%	67.6%	3.33%
Free Cash Flow (FCF) ¹	84.18	58.59	9.43	-100.4	-69.22	-72.45	-49.97	30.7
Change	-	-30.4%	-83.9%	-1,164.99%	31.07%	-4.66%	31.03%	161.44%
Announcement Date	2/25/21	2/24/22	2/23/23	2/22/24	2/27/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: NovoCure Limited

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	8%	-6.37%	-14.67%	-43.57%	-26.31%	-22.21%	-21.88%	-13.12%
EBIT Margin (%)	-	6.15%	-8.29%	-16.64%	-45.72%	-28.17%	-24.04%	-22.7%	-14.98%
EBT Margin (%)	-	3.66%	-9.73%	-15.22%	-37.64%	-21.67%	-20.65%	-21.31%	-14.61%
Net margin (%)	-	4.01%	-10.91%	-17.2%	-40.65%	-27.86%	-23.93%	-24.79%	-16.62%
FCF margin (%)	-	17.03%	10.95%	1.75%	-19.72%	-11.44%	-11.05%	-7.23%	4.01%
FCF / Net Income (%)	-	424.98%	-100.4%	-10.19%	48.51%	41.05%	46.2%	29.17%	-24.13%
Profitability
ROA	-0.09%	2.51%	-2.49%	-4.77%	-12.09%	-8.77%	-	-	-
ROE	-4.38%	5.71%	-13.16%	-21.73%	-51.52%	-46.67%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	4.94x	-10.37x	-5.71x	-1.48x	-	-	-	-
Debt / Free cash flow	-	2.32x	6.03x	47.74x	-3.27x	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	3.03%	4.52%	3.97%	5.32%	7.08%	2.73%	4.34%	4.05%
CAPEX / EBITDA (%)	-	37.84%	-70.92%	-27.07%	-12.21%	-26.91%	-12.3%	-19.85%	-30.88%
CAPEX / FCF (%)	-	17.78%	41.26%	226.49%	-26.98%	-61.91%	-24.71%	-60.04%	100.98%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	4.657	3.948	-	-	-	-	-	-
Change	-	-	-15.21%	-	-	-	-	-	-
EPS ¹	-	0.2	-0.56	-0.88	-1.95	-1.56	-1.396	-1.489	-1.128
Change	-	-	-380%	-57.14%	-121.59%	20%	10.53%	-6.65%	24.2%
Nbr of stocks (in thousands)	-	101,797	103,819	104,950	106,861	108,201	111,982	111,982	111,982
Announcement Date	-	2/25/21	2/24/22	2/23/23	2/22/24	2/27/25	-	-	-